^
    Back
    Association details:
    Biomarker:BRCA1 mutation
    Cancer:Pancreatic Adenocarcinoma
    Regimen:FOLFIRINOX (5-fluorouracil + irinotecan + leucovorin calcium + oxaliplatin)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: A2 - Guideline
    New
    Source:
    NCCN
    Excerpt:
    Preferred Regimens...Only for known BRCA1/2 or PALB2 mutations...FOLFIRINOX or modified FOLFIRINOX…
    Evidence Level:
    Sensitive: C4 – Case Studies
    Source:
    BMJ Case Rep
    Title:

    Response in BRCA1 mutation carrier with metastatic pancreatic adenocarcinoma treated with FOLFIRINOX

    Published date:
    04/29/2022
    Excerpt:
    A woman in her 50s previously treated for early-stage breast cancer, parotid mucoepidermoid carcinoma and Caroli's disease was diagnosed with stage IV pancreatic ductal adenocarcinoma (PDAC) metastatic to the liver and was found to harbour a BRCA1 germline mutation. She had palliative chemotherapy, initially with 5-fluorouracil, leucovorin, irinotecan and oxaliplatin, and then FOLFIRI and capecitabine, achieving a sustained near-complete response for at least 86 months.
    DOI:
    10.1136/bcr-2022-249370